Literature DB >> 16409429

A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation.

J-R Malagelada1.   

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Characterised by abdominal pain or discomfort, bloating and altered bowel habit, IBS is a chronic recurring condition, typically affecting up to 15% of the Western population, IBS can be subclassified into IBS with constipation (IBS-C), IBS with diarrhoea (IBS-D), or IBS with alternating constipation or diarrhoea symptoms (IBS-A). Conventional clinical diagnosis focuses on excluding all potential organic causes of patient symptoms. However, a positive diagnosis of IBS may be established using published criteria such as the Manning and/or Rome criteria. While these methods are useful to identify patients with IBS who are suitable for enrollment into clinical trials, the criteria are relatively complex and not readily applicable to general practice. In this review we present an 'identify, eliminate, probe' algorithm that may be appropriate to establish a positive diagnosis of patients with IBS-C, as symptoms characteristic of patients in this IBS subgroup are least likely to be confused with symptoms reflecting serious organic disease.

Entities:  

Mesh:

Year:  2006        PMID: 16409429     DOI: 10.1111/j.1368-5031.2005.00744.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  15 in total

1.  Latent structure of irritable bowel syndrome symptom severity.

Authors:  Fabian Jasper; Boris Egloff; Andrea Roalfe; Michael Witthöft
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 2.  New treatments for IBS.

Authors:  Magnus Halland; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

Review 3.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Prevalence of restless legs syndrome in patients with irritable bowel syndrome.

Authors:  P Patrick Basu; N James Shah; Nithya Krishnaswamy; Tommy Pacana
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

5.  The impact of digestive and colon drugs on the human hormones profile.

Authors:  Emad F Eskander; Ahmed A Abd-Rabou; Hanaa H Ahmed
Journal:  Indian J Clin Biochem       Date:  2013-03-26

Review 6.  Cognitive-behavioral therapy for the management of irritable bowel syndrome.

Authors:  Qing-Lin Tang; Guo-Yao Lin; Ming-Qing Zhang
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

7.  Irritable bowel syndrome: physicians' awareness and patients' experience.

Authors:  Linda Bjork Olafsdottir; Hallgrímur Gudjonsson; Heidur Hrund Jonsdottir; Jon Steinar Jonsson; Einar Bjornsson; Bjarni Thjodleifsson
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

8.  Knowledge, attitudes, and practices of primary care physicians about irritable bowel syndrome in Northern Saudi Arabia.

Authors:  Ahmad H Al-Hazmi
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

9.  Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.

Authors:  Peter Layer; Jutta Keller; Helena Loeffler; Andreas Kreiss
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

10.  Antispasmodic and antidiarrhoeal activities of 6-(4-hydroxy-3-methoxyphenyl)-hexanonic acid from Pycnocycla spinosa Decne. exBoiss.

Authors:  H Sadraei; M Ghanadian; G Asghari; E Madadi; N Azali
Journal:  Res Pharm Sci       Date:  2014 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.